Chugai Pharmaceutical Co., Ltd. (CHGCY)
OTCMKTS: CHGCY · Delayed Price · USD
12.87
-0.12 (-0.93%)
Jun 29, 2022 4:00 PM - Market closed
-0.93%
(1D)
| Market Cap | 43.01B |
| Revenue (ttm) | 8.72B |
| Net Income (ttm) | 2.84B |
| Shares Out | 3.34B |
| EPS (ttm) | 0.87 |
| PE Ratio | 14.76 |
| Forward PE | 18.21 |
| Dividend | $0.33 (2.53%) |
| Ex-Dividend Date | Jun 29, 2022 |
| Volume | 138,868 |
| Open | 12.55 |
| Previous Close | 12.99 |
| Day's Range | 12.55 - 13.01 |
| 52-Week Range | 11.88 - 20.75 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 16.58 (+28.8%) |
| Earnings Date | n/a |
About CHGCY
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product... [Read more...]
Industry
Drug Manufacturers-General
Founded
1925
CEO
Tatsuro Kosaka
Employees
7,664
Stock Exchange
OTCMKTS
Ticker Symbol
CHGCY
Analyst Forecast
According to 17 analysts, the average rating for CHGCY stock is "Buy." The 12-month stock price forecast is 16.58, which is an increase of 28.83% from the latest price.
Price Target
$16.58
(28.83% upside)
Analyst Consensus: Buy